Cubist Systematic Strategies, LLC Acumen Pharmaceuticals, Inc. Transaction History

Cubist Systematic Strategies, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$2.14 - $4.01 $13,875 - $26,000	6,484 Added 270.62%	8,880 $21,000
Q1 2024 May 15, 2024	SELL	$2.97 - $4.64 $93,581 - $146,201	-31,509 Reduced 92.93%	2,396 $9,000
Q4 2023 Feb 14, 2024	BUY	$1.86 - $4.48 $63,063 - $151,894	33,905 New	33,905 $130,000
Q2 2023 Aug 14, 2023	SELL	$3.59 - $6.59 $6,400 - $11,749	-1,783 Reduced 11.97%	13,116 $63,000
Q1 2023 May 15, 2023	SELL	$3.75 - $6.65 $11,598 - $20,568	-3,093 Reduced 17.19%	14,899 $60,000
Q4 2022 Feb 14, 2023	SELL	$4.81 - $10.17 $23,809 - $50,341	-4,950 Reduced 21.58%	17,992 $97,000
Q3 2022 Nov 14, 2022	SELL	$4.44 - $10.48 $4,289 - $10,123	-966 Reduced 4.04%	22,942 $230,000
Q2 2022 Aug 15, 2022	BUY	$3.08 - $4.88 $57,044 - $90,382	18,521 Added 343.81%	23,908 $112,000
Q1 2022 May 16, 2022	SELL	$3.91 - $6.73 $24,077 - $41,443	-6,158 Reduced 53.34%	5,387 $21,000
Q4 2021 Feb 14, 2022	BUY	$6.54 - $15.31 $75,504 - $176,753	11,545 New	11,545 $78,000

40.6M

28.6K

76.4K

Ticker ABOS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,503,100
Market Cap $56.3M
Description
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Ph...

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.